Atopic dermatitis

Akeso to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Share Its Corporate & Innovative Clinical Development Roadmap

Retrieved on: 
Monday, January 8, 2024
Monoclonal antibody, Immunotherapy, NPC, Atopic dermatitis, Hepatocellular carcinoma, Shanda, Cervical cancer, PD-1, EGFR, CDE, Anemia, NDA, HCC, Cohort, Death, Bevacizumab, NMPA, Ankylosing spondylitis, Summit, Patient, ADC, NSCLC, Hypercholesterolemia, PCSK9, Pembrolizumab, Pharmaceutical industry

Ivonescimab is expected to become the world's first bispecific drug combining immunotherapy and anti-angiogenesis.

Key Points: 
  • Ivonescimab is expected to become the world's first bispecific drug combining immunotherapy and anti-angiogenesis.
  • Potential initiation of a Phase III clinical trial for manfidokimab (IL-4R) for the treatment of moderate atopic dermatitis.
  • Over the next five years, Akeso has high expectations of launching around 10 internally developed blockbuster drugs, both in China and worldwide, thereby achieving successful commercialization.
  • Akeso has established and continuously advances its integrated and efficient system of discovery, development, production, and sales of its innovative drugs and pipeline candidates.

selectION, Inc. to Present Update on Clinical Progress at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on January 11, 2024

Retrieved on: 
Friday, January 5, 2024
Selection, Immunocompetence, Conference, Atopic dermatitis, Safety, Patient, KCNA3, Disease, Pharmaceutical industry

San Diego, CA, USA, and Munich, Germany – January 5, 2024 - selectION, Inc., a clinical-stage biopharmaceutical company developing novel treatments for T cell mediated autoimmune diseases, today announced that management will present at the 42nd Annual J.P. Morgan Healthcare Conference.

Key Points: 
  • San Diego, CA, USA, and Munich, Germany – January 5, 2024 - selectION, Inc., a clinical-stage biopharmaceutical company developing novel treatments for T cell mediated autoimmune diseases, today announced that management will present at the 42nd Annual J.P. Morgan Healthcare Conference.
  • The presentation will be held Thursday, January 11, 2024, 08:00 AM - 08:25 AM PST at Golden Gate (32nd Floor), The Westin.
  • Blocking the target with a high-affinity molecule results in specific deactivation of the disease associated cell clone and induction of immunoregulatory processes.
  • As such, si-544 presents a compelling pipeline opportunity in the treatment of T cell mediated autoimmune diseases.

R&D Day Highlights Kymera’s Immunology Strategy and Emerging Pipeline of Novel, First-in-Class Oral Degraders Addressing Multiple Highly Prevalent Immuno-inflammatory Diseases

Retrieved on: 
Thursday, January 4, 2024
Janus, Atopic dermatitis, Receptor (biochemistry), Sanofi, Janus kinase, Hidradenitis suppurativa, Eosinophilic esophagitis, Autoimmunity, Inflammatory bowel disease, HS, Inflammation, Lupus, Blood, TLR, Therapy, Clinical trial, Asthma, JAK, Dupilumab, Roflumilast, Polyp (medicine), TPD, Webcast, Patient, Psoriasis, TYK2, STAT6, Skin, Sinusitis, Pharmaceutical industry

As part of its strategy, Kymera is unveiling two new programs that each have the potential to address multiple immune-mediated diseases, each with considerable market potential.

Key Points: 
  • As part of its strategy, Kymera is unveiling two new programs that each have the potential to address multiple immune-mediated diseases, each with considerable market potential.
  • Kymera will share its immunology strategy, including market insights, program updates, new preclinical data and development timelines, at its virtual R&D Day this morning.
  • In addition, at low oral doses, KT-621 demonstrated near full in vivo STAT6 degradation and was well-tolerated in multiple preclinical toxicity studies.
  • Kymera will host a webcast to discuss its emerging immunology pipeline from 10:00 a.m. – 12:00 p.m.

Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases

Retrieved on: 
Thursday, January 4, 2024
FDA, Health, Clinical Trials, Pharmaceutical, Optical, Biotechnology, Alcoholism, Atopic dermatitis, Cholesterol, Metabolism, Multimedia, IND, Alcoholic hepatitis, Disease, Mortality, AMD, Body surface area, Therapy, MELD, Clinical trial, Hospital, Telecanthus, DSM-IV codes, Spasticity, Protocol, Cirrhosis, Biomarker, Triglyceride, Syndrome, Ethanol, Patient, Safety, RASP, Retina, Pharmaceutical industry

ADX-629, administered twice daily over 90 days, has completed initial clinical testing in three adult patients in an investigator-sponsored clinical trial.

Key Points: 
  • ADX-629, administered twice daily over 90 days, has completed initial clinical testing in three adult patients in an investigator-sponsored clinical trial.
  • Highlighting the advancement of the RASP platform and the selection of key clinical indications for future development, Aldeyra released a focused pipeline.
  • “With the success achieved in our ADX-629 program, which includes a number of positive, signal-finding clinical results, we are excited to advance our RASP modulator pipeline to systemic and retinal immune-mediated diseases, as well as metabolic diseases, exacerbated by RASP,” stated Dr. Brady.
  • “We anticipate 2024 to provide a variety of clinical-stage catalysts, as Aldeyra continues to progress its novel RASP platform.”

Generate:Biomedicines Fortifies Leadership in Generative AI with Advancing Clinical Pipeline and Expanded Amgen Collaboration, Overviewed at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Thursday, January 4, 2024
Software, Research, General Health, Pharmaceutical, Technology, Artificial Intelligence, Clinical Trials, Science, Biotechnology, Other Technology, Other Science, Health, Westin St. Francis, Conference, Atopic dermatitis, Protein, Learning, Cryogenic electron microscopy, Flagship Pioneering, Gateway, AMGN, Generative, Biomedicine, Biomarker, SARS-CoV-2, Safety, Therapy, Vaccine

Mike Nally, Chief Executive Officer, will overview these updates, as well as share more about the company’s strategy to further strengthen its leadership in generative biology, at the 42nd Annual J.P. Morgan Healthcare Conference, which will be occurring from January 8-11 in San Francisco.

Key Points: 
  • Mike Nally, Chief Executive Officer, will overview these updates, as well as share more about the company’s strategy to further strengthen its leadership in generative biology, at the 42nd Annual J.P. Morgan Healthcare Conference, which will be occurring from January 8-11 in San Francisco.
  • The presentation will take place on January 10 from 10:00-10:25am PST at the Golden Gate (32nd Floor) of The Westin St. Francis.
  • Deploying structure in the learning loop utilizing CryoEM to generate data for iterative learning which has shown faster, improved outcomes.
  • “We look forward to working even more closely together in order to deliver best-in-class therapies that address significant unmet patient needs.”

Apogee Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Tuesday, January 2, 2024
Conference, Atopic dermatitis, COPD, Chronic obstructive pulmonary disease, SAN, Therapy, I&I, Asthma, News

SAN FRANCISCO and WALTHAM, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other inflammatory and immunology (I&I) indications, today announced that Michael Henderson, M.D., Chief Executive Officer of Apogee, will present at the 42nd Annual J.P. Morgan Conference on Tuesday, January 9, 2024 at 7:30 a.m. P.T.

Key Points: 
  • SAN FRANCISCO and WALTHAM, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other inflammatory and immunology (I&I) indications, today announced that Michael Henderson, M.D., Chief Executive Officer of Apogee, will present at the 42nd Annual J.P. Morgan Conference on Tuesday, January 9, 2024 at 7:30 a.m. P.T.
  • / 10:30 a.m. E.T.
  • A live and archived webcast of the presentation will be available via the News & Events page in the Investors section of the Apogee Therapeutics website.

Aclaris Therapeutics Provides Corporate Update

Retrieved on: 
Tuesday, December 19, 2023
Workforce, Atopic dermatitis, Osteoporosis, Therapy, Clinical trial, Pharmacokinetics, Kinect, Professional, MK2, Pancreatic cancer, Patient, Safety, ACRS, Ulcerative colitis, Pharmaceutical industry

WAYNE, Pa., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, today announced several corporate updates.

Key Points: 
  • WAYNE, Pa., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, today announced several corporate updates.
  • First, Aclaris announced the publication of the Phase 2a trial results of ATI-1777 in moderate to severe atopic dermatitis (AD) in the peer-reviewed journal JID Innovations on November 27, 2023.
  • Based on these results, Aclaris progressed ATI-1777 into a Phase 2b trial in patients with mild to severe AD.
  • Aclaris plans to use ATI-450 instead of ATI-2231, its second MK2 inhibitor, due to ATI-450’s more advanced clinical development package.

Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelikefalin for Moderate-to-Severe Pruritus in Patients with Atopic Dermatitis

Retrieved on: 
Monday, December 18, 2023
Atopic dermatitis, Notalgia paresthetica, Itch, BID, TCS, MD, Therapy, NRS, Week, KIND, Tablet, Patient, Safety, CKD, Pharmaceutical industry

STAMFORD, Conn., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the outcome from the dose-finding Part A of the KIND 1 study evaluating the efficacy and safety of oral difelikefalin as adjunct therapy to topical corticosteroids (TCS) for moderate-to-severe pruritus in adult patients with atopic dermatitis (AD). Oral difelikefalin as adjunct to TCS did not demonstrate a meaningful clinical benefit compared to TCS alone, resulting in the Company’s decision to discontinue its clinical program in pruritus associated with atopic dermatitis.

Key Points: 
  • Oral difelikefalin as adjunct to TCS did not demonstrate a meaningful clinical benefit compared to TCS alone, resulting in the Company’s decision to discontinue its clinical program in pruritus associated with atopic dermatitis.
  • “We are disappointed with the outcome of this study recognizing that comparing the adjunctive use of oral difelikefalin with TCS to TCS alone represented a high clinical bar based on anticipated real-world commercial use.
  • Oral difelikefalin as adjunct therapy to TCS did not demonstrate a meaningful clinical benefit compared to TCS alone.
  • Oral difelikefalin was generally well tolerated with a safety profile similar to prior trials.

ASLAN Pharmaceuticals Provides Year-End Update on Its Eblasakimab and Farudodstat Programs

Retrieved on: 
Tuesday, December 12, 2023
Liver, Atopic dermatitis, Eosinophilic bronchitis, Partnership, Dermatology, ASLN, Alopecia areata, Hair loss, Disease, MD, SAN, JAK, Beacon Grand Hotel, IGA, EASI, Institutional review board, TREK, DHODH, Patient, Safety, AA, Skin

SAN MATEO, Calif. and SINGAPORE, Dec. 12, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Ltd. (Nasdaq: ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today provided a business update and updates related to its programs, eblasakimab and farudodstat.

Key Points: 
  • SAN MATEO, Calif. and SINGAPORE, Dec. 12, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Ltd. (Nasdaq: ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today provided a business update and updates related to its programs, eblasakimab and farudodstat.
  • “Throughout 2023, ASLAN made major progress on multiple fronts – advancing both of our lead programs, eblasakimab and farudodstat in Phase 2 testing, and establishing business development collaborations to further the development and utilization of eblasakimab,” said Dr Carl Firth, Chief Executive Officer, ASLAN Pharmaceuticals.
  • ASLAN will provide an update in early 2024 on the timing of the expected topline readout from the study in 2024.
  • Publication and presentation of further data from the TREK-AD study of eblasakimab, including biomarker data, and on farudodstat at major congresses.

Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma

Retrieved on: 
Tuesday, December 12, 2023
Patient, Entrepreneurship, Atopic dermatitis, Food, Allergy, Internal medicine, Asthma, ACQ, Freedom, Wheeze, Week, COVID-19, Periodic breathing, Congress, Webcast, Cough, Pharmaceutical industry

Improvement was evident as early as Week 1 and statistically significant starting at Week 2 through Week 24 for both doses of rademikibart.

Key Points: 
  • Improvement was evident as early as Week 1 and statistically significant starting at Week 2 through Week 24 for both doses of rademikibart.
  • Additionally, there were strong trends toward prolonging the time to first exacerbation in both rademikibart groups compared to placebo.
  • “We are thrilled with the results of our global Phase 2b study in asthma showing clinically meaningful and sustained improvement in lung function with both high and low doses of rademikibart showing improvement as early as Week 1,” commented Zheng Wei, Ph.D., Co-Founder and CEO of Connect Biopharma.
  • “In the Phase 2b global asthma trial, strong efficacy data was seen in the rademikibart groups, with improvements in airflow and daily asthma symptoms observed rapidly within the first week of treatment.